Results 81 to 90 of about 6,775 (167)

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2162-2170, July 2026.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

Obinutuzumab for relapsed or refractory indolent non-Hodgkin’s lymphomas [PDF]

, 2016
International audienceThe use of anti-CD20 monoclonal antibodies (mAbs), such as rituximab, in CD20-positive B-cell malignancies has dramatically improved the outcome of chronic lymphoid leukemia and non-Hodgkin's lymphomas (NHL). However, the occurrence
Gabellier, Ludovic, Cartron, Guillaume
core   +1 more source

Chronic Enterovirus Meningitis with Acute Hepatitis in a Patient with Chronic Lymphocytic Leukemia Treated with Venetoclax/Obinutuzumab: A Case Report

Case Reports in Oncology
Introduction: Enterovirus infection is typically asymptomatic with rapid host clearance. However, several cases of disseminated enterovirus infection in oncologic patients with obinutuzumab-induced hypogammaglobulinemia have been reported in ...
Kaya L. Curtis, Elizabeth M. Corley, Lee S. Gottesdiener, Erika M. Hissong, Alyson Kaplan, Lindsey E. Roeker, Rosy Priya L. Kodiyanplakkal   +6 more
doaj   +1 more source

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis [PDF]

Background: Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving standard therapy.
Zuta Santillán, Adolfina Elizabeth, Pendergraft, William F, Aroca-Martínez, Gustavo, Omachi, Theodore A, Raghu, Harini, Yoo, Bongin, Garg, Jay P, Navarro Sandoval, Cleyber, Irazoque Palazuelos, Fedra, Martins, Elsa, Rovin, Brad H, Alvarez, Damaris, Tumlin, James A, Kirchner, Petra, Malvar, Ana, Furie, Richard A, Sehgal, Himanshi, Ross Terres, Jorge, Hassan, Imran, Santiago, Mittermayer B, Saxena, Amit, Schindler, Thomas, Pasquale Esposito, Lila, Alexander M   +23 more
core   +1 more source

Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)

OncoImmunology, 2018
Treatment with monoclonal antibodies has revolutionized clinical medicine, especially in the fields of cancer and immunology. One of the oldest antibodies, which is widely used for the treatment of lymphomas and autoimmune diseases, is the anti-CD20 ...
Shlomo Elias, Shira Kahlon, Rebecca Kotzur, Noah Kaynan, Ofer Mandelboim   +4 more
doaj   +1 more source

Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review

Frontiers in Immunology
Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody that is widely used in B-cell lymphomas including follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Kun Kou, Qiaolin Zhou, Lijun Du, Fang Xu
doaj   +1 more source

Venetoclax en combinació amb obinutuzumab per al tractament de primera línia de la leucèmia limfocítica crònica [PDF]

, 2022
Venetoclax; Obinutuzumab; Leucèmia limfocítica crònicaVenetoclax; Obinutuzumab; Leucemia linfocítica crónicaVenetoclax; Obinutuzumab; Chronic lymphocytic leukemiaLa leucèmia limfocítica crònica (LLC) és el tipus més freqüent de leucèmia en l’edat adulta ...
Programa d'Harmonització Farmacoterapèutica
core  

Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study

Virology Journal
Background Patients treated with anti-CD20 monoclonal antibodies could have a higher risk of adverse outcomes of coronavirus disease 2019 (COVID-19). The novel anti-CD20 monoclonal antibody obinutuzumab has shown greater B-cell depletion and superior in ...
Wenxiu Shu, Qianqian Yang, Jing Le, Qianqian Cai, Hui Dai, Liufei Luo, Jiaqi Tong, Yanping Song, Bingrong Chen, Dengbing Chen, Dian Jin   +10 more
doaj   +1 more source

Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study

Frontiers in Immunology
BackgroundPatients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL) with high-tumor burden represent a subset with unfavorable prognosis.
Xin Wan, Dechuan Liu, Haotian Wang, Wei Guo, Xingtong Wang, Yangzhi Zhao, Ou Bai   +6 more
doaj   +1 more source

Safety of Obinutuzumab in Children With Autoimmune Encephalitis and Early B-Cell Repopulation on Rituximab [PDF]

International audienceOBJECTIVEThe study objective was to report the use and safety of obinutuzumab in rituximab-resistant children with neurological inflammatory diseases.METHODSThis study was a single-center retrospective cohort study about all the ...
Cisternino, Salvatore, Sarda, Eugénie, Bustamante, Jacinta, Mesples, Bettina, Fayard, Claire, Aubart, Mélodie, Nguyen, Ai-Tien, Gins, Clarisse, Cotteret, Camille, Durrleman, Chloé, Desguerre, Isabelle   +10 more
core   +1 more source